Carlos Eduardo de Melo Amaral
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Carlos Eduardo de Melo Amaral has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Katarine Antonia dos Santos Barile
Gerência de Biologia Celular e Molecular, Fundação Centro de Hemoterapia e Hematologia do Pará, Brazil
5 shared publications - Carolina de Alcântara Maneschy
Centro de Hemoterapia e Hematologia do Para
4 shared publications - Jairo Augusto Américo de Castro
Centro de Hemoterapia e Hematologia do Pará, Gerência de Biologia Molecular, Belém, PA, Brazil
4 shared publications - Maurício Koury Palmeira
Gerência de Biologia Celular e Molecular, Fundação Centro de Hemoterapia e Hematologia do Pará, Brazil
4 shared publications - Renata Bezerra Hermes de Castro
Fundação Centro de Hematologia e Hemoterapia do Pará
2 shared publications - Adna dos Santos Caldas
Centro Universitário Metropolitano da Amazônia, Belém, PA, Brazil
1 shared publication
Latest Publications
- Open Access
- 10 September 2025
- Published by Elsevier in The Brazilian Journal of Infectious Diseases
- Vol. 29 (6) , 104577
Molecular characterization of Human T-cell Lymphotropic Viruses 1 and 2 (HTLV-1 and HTLV-2) in samples from blood donation candidates in the state of Pará, Brazilian Amazon
- 10 September 2025
- Published by Elsevier in The Brazilian Journal of Infectious Diseases
- Vol. 29 (6) , 104577
Open AccessMolecular characterization of Human T-cell Lymphotropic Viruses 1 and 2 (HTLV-1 and HTLV-2) in samples from blood donation candidates in the state of Pará, Brazilian Amazon
- Open Access
- 6 September 2022
- Published by Revista Ciencias em Saude in REVISTA CIÊNCIAS EM SAÚDE
- Vol. 12 (3) , 61-66
Association between the BCR-ABL gene transcripts and the laboratory hematological profile
Objective: This study describes the hematological parameters associated with the BCR-ABL gene transcripts in patients with chronic myeloid leukemia (CML). Methods: We reviewed the results of 100 detectable patients for one of the BCR-ABL gene transcripts. The eligibility criteria were based on the presence of one of the leukemic transcripts (b2a2, b3a2, and b2a2/b3a2) and complete epidemiological and hematological data. The data were obtained from the LabMaster computerized system. The Kruskal-Wallis test was used to compare the medians of the quantitative variables between the transcripts of the BCR-ABL gene and the chi-square test to compare the qualitative ones, adopting the p-value with a level of significance less than or equal to 0.05. Results: Forty-five patients (45%) presented the b2a2 transcript, 24 (24%) the b3a2 transcript and 31 (31%) a b2a2/b3a2 coexpression. Individuals who expressed the b3a2 transcript had higher leukocyte counts and platelet levels, but we found no differences compared with individuals who expressed the other transcript. Conclusion: In this study, the BCR-ABL gene transcripts did not influence the hematological parameters of patients with CML.
- 6 September 2022
- Published by Revista Ciencias em Saude in REVISTA CIÊNCIAS EM SAÚDE
- Vol. 12 (3) , 61-66
Open AccessAssociation between the BCR-ABL gene transcripts and the laboratory hematological profile
Objective: This study describes the hematological parameters associated with the BCR-ABL gene transcripts in patients with chronic myeloid leukemia (CML). Methods: We reviewed the results of 100 detectable patients for one of the BCR-ABL gene transcripts. The eligibility criteria were based on the presence of one of the leukemic transcripts (b2a2, b3a2, and b2a2/b3a2) and complete epidemiological and hematological data. The data were obtained from the LabMaster computerized system. The Kruskal-Wallis test was used to compare the medians of the quantitative variables between the transcripts of the BCR-ABL gene and the chi-square test to compare the qualitative ones, adopting the p-value with a level of significance less than or equal to 0.05. Results: Forty-five patients (45%) presented the b2a2 transcript, 24 (24%) the b3a2 transcript and 31 (31%) a b2a2/b3a2 coexpression. Individuals who expressed the b3a2 transcript had higher leukocyte counts and platelet levels, but we found no differences compared with individuals who expressed the other transcript. Conclusion: In this study, the BCR-ABL gene transcripts did not influence the hematological parameters of patients with CML.
- Open Access
- 27 August 2022
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 45 (4) , 428-434
Correlation of serological and molecular markers in the screening for hepatitis B virus in blood bank in northern Brazil
- 27 August 2022
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 45 (4) , 428-434
Open AccessCorrelation of serological and molecular markers in the screening for hepatitis B virus in blood bank in northern Brazil
- Open Access
- 15 July 2022
- Published by Universidade de São Paulo. Agência de Bibliotecas e Coleções Digitais in Revista de Medicina
- Vol. 101 (4)
O impacto da automação da fenotipagem eritrocitária estendida na rotina de um serviço de hemoterapia
Objetivos. Avaliar o impacto da automação na fenotipagem eritrocitária expandida e o nível de concordância dessa com a metodologia manual em amostras de doadores de sangue atendidos no hemocentro coordenador da Fundação Hemopa no período de janeiro a dezembro de 2019. Material e Métodos. Foram analisadas 2.700 fenotipagens eritrocitárias realizadas por metodologia manual e automatizada através do equipamento IH500 da BioRad®. Os resultados foram testados quanto ao nível de concordância através do teste de Coeficiente Kappa. Resultados. Das amostras fenotipadas 98,6% (2.662/2.700) foram concordantes em ambas as metodologias e apenas 1,4% (38/2700) foram discordantes. Das 38 amostras discordantes 31,6% referiram-se ao fenótipo Lu(b); 15,8% ao fenótipo Lu(a); 13,1% ao fenótipo Fy(b); 7,9% aos fenótipos Le(b), E, c; 5,3% aos fenótipos N, S, s, Kp(a), P1; e 2,6% aos fenótipos M, Jk(a), Jk(b), Fy(a). Conclusões. O nível de concordância entre os dados obtidos através das técnicas de fenotipagem eritrocitária manual e automatizada foi de 98,6%. Já a implantação dessa metodologia teve um impacto positivo com o aumento em 1.649 amostras processadas a mais em relação ao mesmo período do ano anterior.
- 15 July 2022
- Published by Universidade de São Paulo. Agência de Bibliotecas e Coleções Digitais in Revista de Medicina
- Vol. 101 (4)
Open AccessO impacto da automação da fenotipagem eritrocitária estendida na rotina de um serviço de hemoterapia
Objetivos. Avaliar o impacto da automação na fenotipagem eritrocitária expandida e o nível de concordância dessa com a metodologia manual em amostras de doadores de sangue atendidos no hemocentro coordenador da Fundação Hemopa no período de janeiro a dezembro de 2019. Material e Métodos. Foram analisadas 2.700 fenotipagens eritrocitárias realizadas por metodologia manual e automatizada através do equipamento IH500 da BioRad®. Os resultados foram testados quanto ao nível de concordância através do teste de Coeficiente Kappa. Resultados. Das amostras fenotipadas 98,6% (2.662/2.700) foram concordantes em ambas as metodologias e apenas 1,4% (38/2700) foram discordantes. Das 38 amostras discordantes 31,6% referiram-se ao fenótipo Lu(b); 15,8% ao fenótipo Lu(a); 13,1% ao fenótipo Fy(b); 7,9% aos fenótipos Le(b), E, c; 5,3% aos fenótipos N, S, s, Kp(a), P1; e 2,6% aos fenótipos M, Jk(a), Jk(b), Fy(a). Conclusões. O nível de concordância entre os dados obtidos através das técnicas de fenotipagem eritrocitária manual e automatizada foi de 98,6%. Já a implantação dessa metodologia teve um impacto positivo com o aumento em 1.649 amostras processadas a mais em relação ao mesmo período do ano anterior.
- Open Access
- 9 March 2022
- Published by Research, Society and Development in Research, Society and Development
- Vol. 11 (4)
Seroprevalence of the Human T Lymphotropic Virus (HTLV 1 and HTLV 2) in Blood Donor Candidates in the State of Pará, Northern Brazil
The present study describes HTLV seroprevalence in potential blood donors from the Brazilian state of Pará, and the sociodemographic characteristics of the infection in this state. This descriptive, retrospective, and cross-sectional study is based on secondary serological and sociodemographic data on potential blood donors who were rejected for presenting reactive results in the serological HTLV screening between January 2010 and December 2020. The mean HTLV seroprevalence was 0.2%. The highest frequency of reactivity was recorded in first-time donors, women, individuals over 30 years old that were single and had a relatively low level of education. There have been many advances since the discovery of HTLV, although it is still considered to be a neglected etiological agent in Brazil. Further research on data from hematological services will be necessary to refine regional infection profiles, which will be fundamental for the development of adequate prophylactic practises to control and prevent infection, as well the dissemination of information on the dangers of HTLV to the general population.
- 9 March 2022
- Published by Research, Society and Development in Research, Society and Development
- Vol. 11 (4)
Open AccessSeroprevalence of the Human T Lymphotropic Virus (HTLV 1 and HTLV 2) in Blood Donor Candidates in the State of Pará, Northern Brazil
The present study describes HTLV seroprevalence in potential blood donors from the Brazilian state of Pará, and the sociodemographic characteristics of the infection in this state. This descriptive, retrospective, and cross-sectional study is based on secondary serological and sociodemographic data on potential blood donors who were rejected for presenting reactive results in the serological HTLV screening between January 2010 and December 2020. The mean HTLV seroprevalence was 0.2%. The highest frequency of reactivity was recorded in first-time donors, women, individuals over 30 years old that were single and had a relatively low level of education. There have been many advances since the discovery of HTLV, although it is still considered to be a neglected etiological agent in Brazil. Further research on data from hematological services will be necessary to refine regional infection profiles, which will be fundamental for the development of adequate prophylactic practises to control and prevent infection, as well the dissemination of information on the dangers of HTLV to the general population.
- 9 September 2021
- Published by Springer Nature in Brazilian Journal of Microbiology
- Vol. 52 (4) , 2001-2006
Epidemiological and molecular profile of blood donors infected with HTLV-1/2 in the state of Pará, northern Brazil
Background The Human T-lymphotropic virus (HTLV) is a retrovirus of the genus Deltaretrovirus, which belongs to the family Retroviridae. The most important types are HTLV-1 and HTLV-2. It is estimated that between five and 10 million individuals are infected with HTLV-1, worldwide. Studies in the state of Pará indicate that it has the third highest prevalence of HTLV infections of any Brazilian state. The present study describes the epidemiological, serological, and molecular profile of blood donors from the state of Pará that were classified as unfit due to infection by HTLV-1 and 2. Methods The present study is based on a descriptive, retrospective, and cross-sectional review of the epidemiological, serological, and molecular data on blood donations, between January 2015 and December 2019. The data were obtained from the blood bank system and were digitalized to form a database in the Statistical Package for Social Sciences program, version 20. Descriptive statistics were used to determine the absolute and relative frequencies of the qualitative variables. For the quantitative variables, the mean, standard deviation, and minimum and maximum values were calculated. A p < 0.05 significance level was adopted for all analyses. Results A total of 632 samples were analyzed, of which 496 (78%) had no detectable proviral DNA and 136 (22%) had detectable HTLV. The HTLV-1 was detected in most (78%; 106/136) of these samples, while only 30 (22%) were detected for HTLV-2. The HTLV proviral DNA was detected primarily in females (69.1%), with a mean age of 40 years, with the highest frequencies of detection being recorded in single individuals (66.2%), first-time donors (74.3%), and individuals that had graduated high school (44.1%). The molecular confirmation of HTLV showed that three-quarters (78%) of the serologically reactive individuals were negative for either types 1 or 2, so the epidemiological profile of these individuals was significantly different from their detectable profile. Conclusions The HTLV is neglected in Brazil; there is thus a clear need for further research in the area of regional hemotherapy and hematology services, in order to contribute to the definition of regional infection profiles, that will be fundamental to the development of effective prophylactic practices for the prevention of the infection and the dissemination of knowledge on the dangers of HTLV in the community.
- 9 September 2021
- Published by Springer Nature in Brazilian Journal of Microbiology
- Vol. 52 (4) , 2001-2006
Epidemiological and molecular profile of blood donors infected with HTLV-1/2 in the state of Pará, northern Brazil
Background The Human T-lymphotropic virus (HTLV) is a retrovirus of the genus Deltaretrovirus, which belongs to the family Retroviridae. The most important types are HTLV-1 and HTLV-2. It is estimated that between five and 10 million individuals are infected with HTLV-1, worldwide. Studies in the state of Pará indicate that it has the third highest prevalence of HTLV infections of any Brazilian state. The present study describes the epidemiological, serological, and molecular profile of blood donors from the state of Pará that were classified as unfit due to infection by HTLV-1 and 2. Methods The present study is based on a descriptive, retrospective, and cross-sectional review of the epidemiological, serological, and molecular data on blood donations, between January 2015 and December 2019. The data were obtained from the blood bank system and were digitalized to form a database in the Statistical Package for Social Sciences program, version 20. Descriptive statistics were used to determine the absolute and relative frequencies of the qualitative variables. For the quantitative variables, the mean, standard deviation, and minimum and maximum values were calculated. A p < 0.05 significance level was adopted for all analyses. Results A total of 632 samples were analyzed, of which 496 (78%) had no detectable proviral DNA and 136 (22%) had detectable HTLV. The HTLV-1 was detected in most (78%; 106/136) of these samples, while only 30 (22%) were detected for HTLV-2. The HTLV proviral DNA was detected primarily in females (69.1%), with a mean age of 40 years, with the highest frequencies of detection being recorded in single individuals (66.2%), first-time donors (74.3%), and individuals that had graduated high school (44.1%). The molecular confirmation of HTLV showed that three-quarters (78%) of the serologically reactive individuals were negative for either types 1 or 2, so the epidemiological profile of these individuals was significantly different from their detectable profile. Conclusions The HTLV is neglected in Brazil; there is thus a clear need for further research in the area of regional hemotherapy and hematology services, in order to contribute to the definition of regional infection profiles, that will be fundamental to the development of effective prophylactic practices for the prevention of the infection and the dissemination of knowledge on the dangers of HTLV in the community.
- Open Access
- 11 February 2021
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 44 (3) , 352-357
Frequency of antigen Dia on the blood donor population of the Hemocenter coordinator of the Hemopa Foundation
- 11 February 2021
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 44 (3) , 352-357
Open AccessFrequency of antigen Dia on the blood donor population of the Hemocenter coordinator of the Hemopa Foundation